Scancell, the developer of novel immunotherapies for the treatment of cancer, is pleased to announce that it has signed a collaboration and non-exclusive research agreement with a US-based, clinical stage antibody company to assess monoclonal antibodies (mAbs) targeting tumour-associated glycans (TaGs) including those that have been enhanced with Scancell’s proprietary AvidiMab™ technology.
This is the third collaboration agreement evaluating Scancell’s pipeline of anti-TaG mAbs that have been engineered using the Company’s AvidiMab™ technology; conferring these mAbs with the ability to directly kill tumour cells. Today’s announcement follows prior agreements announced in September 2019 and December 2019.
TaGs are glycan motifs that are associated with tumour malignancies and these can be targeted by antibodies, including antibody drug conjugates (ADC) and also adoptive cell therapies such as chimeric antigen receptor (CAR) T cells.
Under the terms of the collaboration and research agreement, this new collaboration partner will conduct preclinical studies to evaluate Scancell’s anti-TaG mAbs for the treatment of cancer.
Dr Cliff Holloway, Chief Executive Officer, Scancell, commented:
“This continued momentum with AvidiMab™ and our tumour-associated glycan antibodies demonstrates the growing excitement around this platform. This is another important collaboration for Scancell and illustrates the future value that this third platform could potentially generate for the Company.”